Company performance
Add to research
Current Price
as of Feb 07, 2025$1.73
P/E Ratio
N/A
Market Cap
$122.33M
Description
Add to research
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVTYX
- Price$1.73-3.35%
Trading Information
- Market cap$122.33M
- Float74.80%
- Average Daily Volume (1m)1,563,628
- Average Daily Volume (3m)1,872,589
- EPS-$2.37
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$35.25M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$38.24M
- EV-$109.73M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B0.44
- Debt/Equity3.96
Documents
Add to research
SEC Filings
Factset Street Account